Journal Information
Vol. 105. Issue 8.
Pages 802-803 (October 2014)
Vol. 105. Issue 8.
Pages 802-803 (October 2014)
Case and Research Letters
Full text access
Topical 0.2% Rapamycin to Treat Facial Angiofibromas and Hypomelanotic Macules in Tuberous Sclerosis
Rapamicina tópica al 0,2% para el tratamiento de angiofibromas faciales y máculas hipomelanóticas en la esclerosis tuberosa
Visits
7177
N. Knöpfela, A. Martín-Santiagoa,
Corresponding author
anahsd@telefonica.net

Corresponding author.
, A. Bauzaa, J.A. Hervásb
a Servicio de Dermatología, Hospital Universitario Son Espases, Palma de Mallorca, Spain
b Instituto Universitario de Ciencias de la Salud-IUNICS, Universidad de las Islas Baleares, Palma de Mallorca, Spain
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Full Text

Tuberous sclerosis is an autosomal dominant neurocutaneous disorder caused by mutations in tumor suppressor genes TSC1 (in chromosome 9q34), which encodes hamartin, and TSC2 (in chromosome 16p13.3), which encodes tuberin. Hamartin and tuberin, under normal circumstances, form a complex that inhibits the mammalian target of rapamycin (mTOR), which plays a crucial role in cell-cycle regulation. Mutations in the TSC1 and TSC2 genes lead to defective functioning of these proteins and result in uncontrolled cell proliferation that is characterized by the formation of hamartomas in multiple organs, including the skin and kidneys, and in the central nervous system.1,2 Rapamycin (sirolimus) is an immunosuppressant that inhibits the mTOR pathway. Its only approved indication is prophylaxis of renal transplant rejection. Thanks to its antineoplastic properties, sirolimus inhibits angiogenesis and tumor cell proliferation, and has also been shown to be effective in reducing the number and size of tumors in patients with tuberous sclerosis. Recent publications suggest that topical rapamycin is effective for treating facial angiofibromas3–7 and reducing hypomelanotic macules8 in patients with tuberous sclerosis.

We report a case of a 13-year-old boy who had been clinically diagnosed with tuberous sclerosis at age 4 months based on the presence of typical manifestations of this condition, namely epilepsy, multiple hypomelanotic macules, and facial angiofibromas. Genetic analysis confirmed sporadic tuberous sclerosis caused by a c5043C>G mutation in exon 38 of the TSC2 gene, changing the sequence to the N1681K variant. Magnetic resonance imaging of the brain showed multiple cortical and subcortical tubers, multiple intraventricular and subependymal hamartomas, and bilateral retinal astrocytomas. Abdominal ultrasound revealed the presence in the liver and kidneys of multiple angiomyolipomas, which were asymptomatic at the time of evaluation. Skin manifestations included facial angiofibromas that appeared gradually, multiple hypomelanotic macules, a periungual fibroma, and a shagreen patch on the back.

With the aim of improving the patient's facial appearance by reducing the number of angiofibromas, we obtained informed consent to start treatment with a 0.2% rapamycin ointment formulated by the hospital pharmacy and provided at no cost to the patient. We prescribed once-daily application 5 days a week, for 12 months.

The ointment was applied only to the face; because of the high cost of the drug preparation we did not consider treating the macules on the trunk and limbs.

After 2 weeks of treatment we began to observe a reduction in the number of facial angiofibromas, with maximum effect observed at 12 weeks. We also noted considerable improvement in the hypomelanotic macules on the patient's face, with similar responses in the glabella and left cheek (Fig. 1).

Figure 1.

Facial angiofibromas and hypomelanotic macules. A, Before treatment. B, After 20 weeks of 0.2% topical rapamycin.

(0.12MB).

Treatment was well tolerated with no local or systemic adverse effects, and plasma rapamycin levels remained below 0.3 ng/mL. We decided to maintain this treatment for a year to prevent the development of new angiofibromas.

Facial angiofibromas are a characteristic feature of tuberous sclerosis. Although benign, they have a considerable psychological impact on patients.

Our case shows that 0.2% topical rapamycin is a safe and effective therapy for both facial angiofibromas and hypomelanotic macules. The high cost of treatment and the lack of an approved indication for topical rapamycin limit the use of this therapeutic agent in daily practice. This is the third case published in the literature describing a marked improvement in hypomelanotic macules, with almost complete remission. The effectiveness of rapamycin against hypomelanotic macules might be explained by the fact that it increases transcription of microphthalmia transcription factor (MITF), which is involved in melanogenic gene expression and in the induction of melanogenesis in melanoma cells.9

In conclusion, the present case further supports the usefulness of topical rapamycin to treat hypomelanotic macules in patients with tuberous sclerosis. However, more patients treated with topical rapamycin are needed in order to establish its safety and long-term effectiveness and to determine the most appropriate treatment regimen.

References
[1]
K.A. Orlova, P.B. Crino.
The tuberous sclerosis complex.
Ann N Y Acad Sci, 1184 (2010), pp. 87-105
[2]
D.N. Franz, B.D. Weiss.
Molecular therapies for tuberous sclerosis and neurofibromatosis.
Curr Neurol Neurosci Rep, 12 (2012), pp. 294-301
[3]
E. Kaufman McNamara, A.R. Curtis, A.B. Fleischer Jr..
Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin.
J Dermatolog Treat, 23 (2012), pp. 46-48
[4]
M.K. Koenig, A.A. Hebert, J. Roberson, J. Samuels, J. Slopis, A. Woerner, et al.
Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: A double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin.
[5]
R.S. Foster, L.J. Bint, A.R. Halbert.
Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: A pilot study of four patients.
Australas J Dermatol, 53 (2012), pp. 52-56
[6]
P. Valerón-Almazán, M. Vitiello, A. Abuchar, F.A. Kerdel.
Topical rapamycin solution to treat multiple facial angiofibromas in a patient with tuberous sclerosis.
Actas Dermosifiliogr, 103 (2012), pp. 165-166
[7]
R. Salido, G. Garnacho-Saucedo, I. Cuevas-Asencio, J. Ruano, M. Galan-Gutierrez, A. Velez, et al.
Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis associated facial angiofibroma.
J EurAcad Dermatol Venereol, 26 (2012), pp. 1315-1318
[8]
M. Wataya-Kaneda, M. Tanaka, A. Nakamura, S. Matsumoto, I. Katayama.
A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex.
Arch Dermatol, 148 (2012), pp. 138-139
[9]
K. Ohguchi, Y. Banno, Y. Nakagawa, Y. Akao, Y. Nozawa.
Negative regulation of melanogenesis by phospholipase D1 through mTOR/p70 S6 kinase 1 signaling in mouse B16 melanoma cells.
J Cell Physiol, 205 (2005), pp. 444-451

Please cite this article as: Knöpfel N, Martín-Santiago A, Bauza A, Hervás JA. Rapamicina tópica al 0,2% para el tratamiento de angiofibromas faciales y máculas hipomelanóticas en la esclerosis tuberosa. Actas Dermosifiliogr. 2014;105:802–803.

Copyright © 2013. Elsevier España, S.L.U. and AEDV
Download PDF
Idiomas
Actas Dermo-Sifiliográficas
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?